DASAMI LAB PRIVATE LTD

Overview

DASAMI LAB PRIVATE LTD is an active pharmaceutical ingredient (API) supplier with 32 active FDA Type II Drug Master Files, covering AMINOCAPROIC ACID; CANAGLIFLOZIN (AMORPHOUS); CANAGLIFLOZIN HEMIHYDRATE; CARBAMAZEPINE USP; CHLORPROMAZINE HYDROCHLORIDE USP; DEXTROMETHORPHAN HYDROBROMIDE USP.

API / Drug Master Files

DASAMI LAB PRIVATE LTD holds 32 active (32 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• MYCOPHENOLATE MOFETIL USPActive2025-11-14
• DEXTROMETHORPHAN POLISTIREXActive2025-08-30
• THEOPHYLLINE ANHYDROUS USPActive2025-07-29
• MAVACAMTENActive2025-03-25
• VILOXAZINE HYDROCHLORIDEActive2024-12-20
• MIDODRINE HYDROCHLORIDE USPActive2024-08-23
• FEBUXOSTATActive2024-01-24
• SUVOREXANT (FORM-II)Active2023-10-25
• LUMATEPERONE TOSYLATEActive2023-07-22
• PITOLISANT HYDROCHLORIDEActive2023-05-09
• MESALAMINE USPActive2022-12-02
• DEXTROMETHORPHAN HYDROBROMIDE USPActive2022-10-31
• VERAPAMIL HYDROCHLORIDE USPActive2022-08-02
• SPIRONOLACTONE USPActive2022-02-04
• FLUVOXAMINE MALEATE USPActive2021-12-01

Showing 15 of 32 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to DASAMI LAB PRIVATE LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.